News Articles

Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc OSAKA, Japan -Sunday 28 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of the proposed acquisition of Shire plc (“Shire”) announced on May 8,...

Takeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin... -Sunday 28 October 2018

– Six Abstracts to be Presented to Highlight the Potential Impact of ADCETRIS® (brentuximab vedotin) for the Treatment of Hodgkin Lymphoma – (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of six...

Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and... -Saturday 27 October 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or “Takeda”) announces that it has today entered into a Senior Short Term Loan Facility Agreement (the “SSTL”) for an aggregate principal amount of up to 500 billion Japanese Yen. The SSTL will finance...

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG®... -Tuesday 23 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective...

Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at... -Monday 22 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance...

Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc -Friday 19 October 2018

(BUSINESS WIRE)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has...

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders -Monday 1 October 2018

(BUSINESS WIRE) -- Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”) today announced that the Company has established the record date...

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of... -Saturday 29 September 2018

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed...

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+... -Sunday 23 September 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG®(brigatinib) as a monotherapy for...

Takeda Reports First Quarter FY2018 Results -Thursday 2 August 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +6.4% with growth in every region Underlying Revenue grew +6.4%, led by Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) displaying strong growth of...

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in... -Friday 27 July 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first pre-specified interim analysis, with ALUNBRIG® (brigatinib)...

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving... -Thursday 19 July 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adult patients...

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically... -Thursday 12 July 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in...

Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc -Tuesday 10 July 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company...

Takeda Global Headquarters Grand Opening -Monday 2 July 2018

Takeda holds the grand opening of Takeda Global Headquarters in Nihonbashi, Tokyo, Japan. With Takeda Global Headquarters as a base, and a symbol of the company’s values, Takeda will further accelerate its transition into a global, values-based R&D-driven biopharmaceutical leader that...

Takeda Announces Term Loan Credit Agreement and Amendment to Bridge Credit Agreement in Connection with Proposed Shire... -Saturday 9 June 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announces that it has today entered into a term loan credit agreement for an aggregate principal amount of up to 7.5 billion USD with leading global financial institutions including J.P. Morgan Chase Bank N.A.,...

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and... -Sunday 20 May 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two upcoming medical meetings: the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 in...

Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance -Monday 14 May 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +5.5% led by Takeda's Growth Drivers Underlying Revenue grew +5.5%, with Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) posting strong underlying...

Proposed Acquisition of Shire plc by Takeda -Wednesday 9 May 2018

Transaction Highlights Brings together complementary positions in gastroenterology (GI) and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines Creates a global, values-based, R&D-driven...

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood ... -Saturday 24 March 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were...